The emergence of COVID-19 has led to a worldwide challenge for the rapid development of vaccines. Several types of safe and effective vaccines have been available in a time frame never seen before. No
Figure 1. ML and CL patients produce IgG antibodies against Leishmania braziliensisantigens. Anti-SLA total IgG (A), IgG1 (B) and IgG2 (C) titers from ML and CL patients, performed by ELISA technique.
